Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Institute of Hematology, Zhejiang University, Hangzhou, China.
Front Immunol. 2021 Feb 24;12:641910. doi: 10.3389/fimmu.2021.641910. eCollection 2021.
Histone deacetylase inhibitors are currently the most studied drugs because of their beneficial effects on inflammatory response. Emerging data from numerous basic studies and clinical trials have shown that histone deacetylase inhibitors can suppress immune-mediated diseases, such as graft-vs.-host disease (GVHD), while retaining beneficial graft-vs.-leukemia (GVL) effects. These drugs prevent and/or treat GVHD by modifying gene expression and inhibiting the production of proinflammatory cytokines, regulating the function of alloreactive T cells, and upregulating the function and number of regulatory T cells. Some of these drugs may become new immunotherapies for GVHD and other immune diseases.
组蛋白去乙酰化酶抑制剂是目前研究最多的药物，因为它们对炎症反应有有益的影响。大量基础研究和临床试验的新数据表明，组蛋白去乙酰化酶抑制剂可以抑制免疫介导的疾病，如移植物抗宿主病 (GVHD)，同时保留有益的移植物抗白血病 (GVL)效应。这些药物通过改变基因表达和抑制促炎细胞因子的产生、调节同种反应性 T 细胞的功能以及上调调节性 T 细胞的功能和数量来预防和/或治疗 GVHD。其中一些药物可能成为 GVHD 和其他免疫性疾病的新免疫疗法。
